Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.53 |
| ▸ | LPL | P06858 | 12/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22448166 | 0.98 | LIPG (0.51) | LIPGLPLP2RX7F11CA1 | |
| SCHEMBL22448147 | 0.95 | LIPG (0.54) | LIPGLPLP2RX7F11CA1 | |
| SCHEMBL31334233 | 0.84 | LIPG (0.43) | LIPGLPLP2RX7ACMSD | |
| SCHEMBL18015261 | 0.80 | DGAT1 (0.44) | LIPGLPLP2RX7F11 | |
| SCHEMBL30919843 | 0.79 | P2RX7 (0.47) | LIPGLPLP2RX7ACMSD | |
| SCHEMBL17368539 | 0.79 | P2RX7 (0.41) | LIPGLPLP2RX7F11CA1 | |
| SCHEMBL31144766 | 0.77 | ATM (0.47) | LIPGLPLP2RX7 | |
| SCHEMBL25160238 | 0.77 | P2RX7 (0.39) | LIPGLPLP2RX7ESR2 | |
| SCHEMBL24608995 | 0.76 | LIPG (0.83) | LIPGLPLF11CA1CA2 | |
| SCHEMBL2707320 | 0.76 | LIPG (0.83) | LIPGLPLF11CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3712147-B1 | SGLTS INHIBITOR AND APPLICATION THEREOF | SHANGDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-10822365-B1 | SGLTS inhibitor and application thereof | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2020-11-03 | — | — | US | disclosed |
| US-20200331950-A1 | SGLTS INHIBITOR AND APPLICATION THEREOF | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-10-22 | — | — | US | disclosed |
| EP-3712147-A1 | SGLTS INHIBITOR AND APPLICATION THEREOF | Shangdong Danhong Pharmaceutical Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-20170107219-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9567330-B2 | Azabenzimidazole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20140194420-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822365-B1 | SGLTS inhibitor and application thereof | SLC5A1, SLC5A2, SLC5A11 | LIPG 731/4885LPL 1016/4885P2RX7 2944/4885 |
| US-20200331950-A1 | SGLTS INHIBITOR AND APPLICATION THEREOF | SLC5A1, SLC5A2, SLC5A11 | LIPG 731/4885LPL 1016/4885P2RX7 2944/4885 |
| US-20170107219-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAB1, PRKAB2, PRKAG1 | LIPG 4187/4885LPL 3579/4885P2RX7 2287/4885 |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | LIPG 1301/4885LPL 3950/4885P2RX7 3525/4885 |
| US-20140194420-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAB1, PRKAB2, PRKAG1 | LIPG 4187/4885LPL 3579/4885P2RX7 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.